{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001205","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.231624+00:00","generated_at":"2026-06-07T02:11:33.132512+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cartesian reports positive 12-month Phase 2a data for Descartes-08 in MG; cash $118M","bullets":["12-month follow-up: 5 of 7 Phase 2a MG patients maintained clinically meaningful improvements ~10 months after last infusion; autoantibodies durably reduced.","Descartes-08 well-tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity; outpatient administration without lymphodepletion.","Phase 2b topline data expected mid-2024; Phase 2 study in SLE to initiate 1H24; IND cleared for next-gen Descartes-15 for multiple myeloma.","Pro forma cash ~$118M as of Dec 31, 2023; expected to fund operations into 2H 2026, through Phase 3 of Descartes-08.","Common shares outstanding: 161.9M; Series A preferred convertible into ~534.3M common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001205","json":"https://secwatch.observer/filing/0001140361-24-001205.json","markdown":"https://secwatch.observer/filing/0001140361-24-001205.md","text":"https://secwatch.observer/filing/0001140361-24-001205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/0001140361-24-001205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/ny20014884x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:11:33.132512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}